CA1297012C - Compositiions pharmaceutiques pour inhalation - Google Patents

Compositiions pharmaceutiques pour inhalation

Info

Publication number: CA1297012C
Authority: CA; Canada
Prior art keywords: excipient; pharmaceutical composition; conglomerate; lactose; powder
Prior art date: 1986-03-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA000531054A

Other languages

English (en)

Inventor

Luciana Pavesi

Paolo Chiesi

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Chiesi Farmaceutici SpA

Original Assignee

Chiesi Farmaceutici SpA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-03-04

Filing date

1987-03-03

Publication date

1992-03-10

1987-03-03 Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA

1992-03-10 Application granted granted Critical

1992-03-10 Publication of CA1297012C publication Critical patent/CA1297012C/fr

2009-03-10 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 22
239000000843 powder Substances 0.000 claims abstract description 39
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 24
239000007787 solid Substances 0.000 claims abstract description 10
239000000314 lubricant Substances 0.000 claims abstract description 9
238000002360 preparation method Methods 0.000 claims abstract description 7
239000003085 diluting agent Substances 0.000 claims abstract 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 26
239000000203 mixture Substances 0.000 claims description 26
GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 24
229940079593 drug Drugs 0.000 claims description 23
239000003814 drug Substances 0.000 claims description 23
239000008101 lactose Substances 0.000 claims description 22
239000002245 particle Substances 0.000 claims description 14
235000019359 magnesium stearate Nutrition 0.000 claims description 13
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 8
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 8
239000004299 sodium benzoate Substances 0.000 claims description 8
235000010234 sodium benzoate Nutrition 0.000 claims description 8
229930006000 Sucrose Natural products 0.000 claims description 7
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 7
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 7
235000013681 dietary sucrose Nutrition 0.000 claims description 7
229960004793 sucrose Drugs 0.000 claims description 7
239000000811 xylitol Substances 0.000 claims description 7
235000010447 xylitol Nutrition 0.000 claims description 7
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 7
229960002675 xylitol Drugs 0.000 claims description 7
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 6
239000007864 aqueous solution Substances 0.000 claims description 6
238000000034 method Methods 0.000 claims description 6
229960002052 salbutamol Drugs 0.000 claims description 6
KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims description 5
229950000210 beclometasone dipropionate Drugs 0.000 claims description 5
239000000126 substance Substances 0.000 claims description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 3
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 3
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims description 2
LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 claims description 2
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
229930195725 Mannitol Natural products 0.000 claims description 2
229960005174 ambroxol Drugs 0.000 claims description 2
JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 claims description 2
PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 2
229960004436 budesonide Drugs 0.000 claims description 2
229960001117 clenbuterol Drugs 0.000 claims description 2
STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 claims description 2
IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims description 2
229960001022 fenoterol Drugs 0.000 claims description 2
229960000676 flunisolide Drugs 0.000 claims description 2
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 2
239000000594 mannitol Substances 0.000 claims description 2
235000010355 mannitol Nutrition 0.000 claims description 2
230000000510 mucolytic effect Effects 0.000 claims description 2
239000003921 oil Substances 0.000 claims description 2
229960000797 oxitropium Drugs 0.000 claims description 2
NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 claims description 2
229960002288 procaterol Drugs 0.000 claims description 2
FKNXQNWAXFXVNW-BLLLJJGKSA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 claims description 2
MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims description 2
229960002720 reproterol Drugs 0.000 claims description 2
WVLAAKXASPCBGT-UHFFFAOYSA-N reproterol Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 WVLAAKXASPCBGT-UHFFFAOYSA-N 0.000 claims description 2
229960000195 terbutaline Drugs 0.000 claims description 2
238000005469 granulation Methods 0.000 claims 2
230000003179 granulation Effects 0.000 claims 2
229920002307 Dextran Polymers 0.000 claims 1
VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 claims 1
239000000150 Sympathomimetic Substances 0.000 claims 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
150000001412 amines Chemical class 0.000 claims 1
230000001078 anti-cholinergic effect Effects 0.000 claims 1
230000001387 anti-histamine Effects 0.000 claims 1
239000000043 antiallergic agent Substances 0.000 claims 1
239000000739 antihistaminic agent Substances 0.000 claims 1
238000000889 atomisation Methods 0.000 claims 1
239000008119 colloidal silica Substances 0.000 claims 1
229960000265 cromoglicic acid Drugs 0.000 claims 1
229960001361 ipratropium bromide Drugs 0.000 claims 1
KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 claims 1
229960005414 pirbuterol Drugs 0.000 claims 1
150000003431 steroids Chemical class 0.000 claims 1
230000001975 sympathomimetic effect Effects 0.000 claims 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
239000008213 purified water Substances 0.000 description 8
239000002775 capsule Substances 0.000 description 6
239000000243 solution Substances 0.000 description 5
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
238000010438 heat treatment Methods 0.000 description 4
238000009826 distribution Methods 0.000 description 3
239000008187 granular material Substances 0.000 description 3
230000029058 respiratory gaseous exchange Effects 0.000 description 3
239000000725 suspension Substances 0.000 description 3
CBQYNPHHHJTCJS-UHFFFAOYSA-N Alline Chemical compound C1=CC=C2C3(O)CCN(C)C3NC2=C1 CBQYNPHHHJTCJS-UHFFFAOYSA-N 0.000 description 2
241000518994 Conta Species 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000012439 solid excipient Substances 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
241000543381 Cliftonia monophylla Species 0.000 description 1
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
238000005276 aerator Methods 0.000 description 1
229940092705 beclomethasone Drugs 0.000 description 1
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229940109248 cromoglycate Drugs 0.000 description 1
208000002925 dental caries Diseases 0.000 description 1
229960002086 dextran Drugs 0.000 description 1
238000007865 diluting Methods 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
239000003172 expectorant agent Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
229960001888 ipratropium Drugs 0.000 description 1
238000005461 lubrication Methods 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
239000004531 microgranule Substances 0.000 description 1
239000003595 mist Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229940066491 mucolytics Drugs 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000006069 physical mixture Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
HJHVQCXHVMGZNC-JCJNLNMISA-M sodium;(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoate Chemical compound [Na+].O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C HJHVQCXHVMGZNC-JCJNLNMISA-M 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
CDXCCYNINPIWGE-UHFFFAOYSA-N thiazinam Chemical compound C1=CC=C2N(CC(C)[N+](C)(C)C)C3=CC=CC=C3SC2=C1 CDXCCYNINPIWGE-UHFFFAOYSA-N 0.000 description 1
229960004003 thiazinam Drugs 0.000 description 1
238000009423 ventilation Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Pulmonology (AREA)
Otolaryngology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

CA000531054A 1986-03-04 1987-03-03 Compositiions pharmaceutiques pour inhalation Expired - Lifetime CA1297012C (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT19625/86A IT1204826B (it)	1986-03-04	1986-03-04	Composizioni farmaceutiche per inalazione
IT19625A/86		1986-03-04

Publications (1)

Publication Number	Publication Date
CA1297012C true CA1297012C (fr)	1992-03-10

Family

ID=11159814

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000531054A Expired - Lifetime CA1297012C (fr)	1986-03-04	1987-03-03	Compositiions pharmaceutiques pour inhalation

Country Status (17)

Country	Link
EP (2)	EP0258356B1 (fr)
JP (1)	JPS63502895A (fr)
KR (1)	KR940000099B1 (fr)
AT (1)	ATE94755T1 (fr)
AU (1)	AU597964B2 (fr)
CA (1)	CA1297012C (fr)
DE (2)	DE258356T1 (fr)
ES (1)	ES2031839T3 (fr)
FI (1)	FI90015C (fr)
GR (2)	GR880300017T1 (fr)
HU (1)	HU202748B (fr)
IT (1)	IT1204826B (fr)
MY (1)	MY102928A (fr)
NO (1)	NO874590L (fr)
NZ (1)	NZ219484A (fr)
WO (1)	WO1987005213A1 (fr)
ZA (1)	ZA871523B (fr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5270305A (en)	1989-09-08	1993-12-14	Glaxo Group Limited	Medicaments
US5208226A (en) *	1989-09-08	1993-05-04	Glaxo Group Limited	Medicaments
GB9001635D0 (en) *	1990-01-24	1990-03-21	Ganderton David	Aerosol carriers
US5376386A (en) *	1990-01-24	1994-12-27	British Technology Group Limited	Aerosol carriers
SE9101090D0 (sv) *	1991-04-11	1991-04-11	Astra Ab	Process for conditioning of water-soluble substances
JPH0558911A (ja) *	1991-08-27	1993-03-09	N D Shinyaku Kaihatsu Kenkyusho:Kk	鎮咳去痰剤
US6794357B1 (en)	1993-06-24	2004-09-21	Astrazeneca Ab	Compositions for inhalation
US5830853A (en)	1994-06-23	1998-11-03	Astra Aktiebolag	Systemic administration of a therapeutic preparation
US6632456B1 (en)	1993-06-24	2003-10-14	Astrazeneca Ab	Compositions for inhalation
GB9322014D0 (en)	1993-10-26	1993-12-15	Co Ordinated Drug Dev	Improvements in and relating to carrier particles for use in dry powder inhalers
AUPM411494A0 (en) *	1994-02-25	1994-03-24	Central Sydney Area Health Service	Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum
GB9404945D0 (en) *	1994-03-15	1994-04-27	Glaxo Group Ltd	Pharmaceutical composition
DE4425255A1 (de)	1994-07-16	1996-01-18	Asta Medica Ag	Formulierung zur inhalativen Applikation
SE9404468D0 (sv) *	1994-12-22	1994-12-22	Astra Ab	Powder formulations
US6524557B1 (en)	1994-12-22	2003-02-25	Astrazeneca Ab	Aerosol formulations of peptides and proteins
JP4155594B2 (ja)	1994-12-22	2008-09-24	アストラゼネカ・アクチエボラーグ	エアゾール製剤
GB9501841D0 (en) *	1995-01-31	1995-03-22	Co Ordinated Drug Dev	Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en) *	1995-07-24	1995-09-20	Co Ordinated Drug Dev	Improvements in and relating to powders for use in dry powder inhalers
US6503537B2 (en) *	1997-03-20	2003-01-07	Schering Corporation	Preparation of powder agglomerates
US6599883B1 (en) *	1998-10-30	2003-07-29	Nastech Pharmaceutical Company, Inc.	Nasal delivery of xylitol
RU2221552C2 (ru) *	1998-11-13	2004-01-20	Джаго Рисерч Аг	Сухой порошок для ингаляции
WO2000053157A1 (fr) *	1999-03-05	2000-09-14	Chiesi Farmaceutici S.P.A.	Compositions pharmaceutiques en poudre ameliorees pour inhalation
ITMI991582A1 (it)	1999-07-16	2001-01-16	Chiesi Farma Spa	Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
GB0009469D0 (en)	2000-04-17	2000-06-07	Vectura Ltd	Improvements in or relating to formalities for use in inhaler devices
PE20011227A1 (es)	2000-04-17	2002-01-07	Chiesi Farma Spa	Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
EP2266549B1 (fr) *	2000-06-27	2019-08-07	Vectura Limited	Procedé permettant de produire des particules destinées à être utilisées dans une composition pharmaceutique
CA2413692C (fr) *	2000-06-27	2011-10-18	Vectura Limited	Procede permettant de produire des particules destinees a etre utilisees dans une composition pharmaceutique
DK2283818T3 (en) †	2000-11-30	2017-10-16	Vectura Ltd	Process for preparing particles for use in a pharmaceutical composition
DK1920763T3 (da) *	2000-11-30	2014-07-07	Vectura Ltd	Farrmaceutiske præparater til inhalation
US8580306B2 (en)	2000-11-30	2013-11-12	Vectura Limited	Particles for use in a pharmaceutical composition
US6681768B2 (en)	2001-06-22	2004-01-27	Sofotec Gmbh & Co. Kg	Powder formulation disintegrating system and method for dry powder inhalers
DE10141377A1 (de) *	2001-08-23	2003-03-13	Boehringer Ingelheim Pharma	Aufstreuverfahren zur Herstellung von Pulverformulierungen
DE10141376A1 (de) *	2001-08-23	2003-03-13	Boehringer Ingelheim Pharma	Verfahren zur Herstellung von Inhalationspulvern
EP1487417A4 (fr)	2001-09-17	2010-03-17	Glaxo Group Ltd	Formulations de medicament en poudre seche
RU2279292C2 (ru) *	2001-10-24	2006-07-10	Пари Гмбх	Набор для приготовления фармацевтической композиции
EP1417961A1 (fr) *	2002-11-08	2004-05-12	Boehringer Ingelheim International GmbH	Nouvelle composition pharmaceutique comprenant une combinaison d'ambroxol ou de bromhexine et d'iodure d'isopropamide
JP2009513529A (ja)	2003-07-11	2009-04-02	グラクソグループリミテッド	ステアリン酸マグネシウムを含む医薬製剤
AR045914A1 (es)	2003-07-17	2005-11-16	Glaxo Group Ltd	Compuesto alcoholico terciario del 8-azoniabiciclo [3.2.1] octano, composicion farmaceutica que lo comprende y su uso para preparar esta ultima
SG147436A1 (en)	2003-10-14	2008-11-28	Glaxo Group Ltd	Muscarinic acetylcholine receptor antagonists
EA200600787A1 (ru)	2003-10-17	2006-08-25	Глэксо Груп Лимитед	Антагонисты мускариновых ацетилхолиновых рецепторов
TW200524577A (en)	2003-11-04	2005-08-01	Glaxo Group Ltd	Muscarinic acetylcholine receptor antagonists
GB0326632D0 (en)	2003-11-14	2003-12-17	Jagotec Ag	Dry powder formulations
WO2005095407A1 (fr)	2004-03-17	2005-10-13	Glaxo Group Limited	Antagonistes du recepteur d'acetylcholine muscarinique m3
MY144753A (en)	2004-04-27	2011-10-31	Glaxo Group Ltd	Muscarinic acetylcholine receptor antagonists
JP2007537261A (ja)	2004-05-13	2007-12-20	グラクソ　グループ　リミテッド	ムスカリン性アセチルコリン受容体アンタゴニスト
US8524735B2 (en)	2005-05-18	2013-09-03	Mpex Pharmaceuticals, Inc.	Aerosolized fluoroquinolones and uses thereof
PL1901749T3 (pl)	2005-05-18	2017-04-28	Horizon Orphan Llc	Fluorochinolony w aerozolu i ich zastosowania
WO2007022351A2 (fr)	2005-08-18	2007-02-22	Glaxo Group Limited	Antagonistes de recepteurs d'acetylcholine muscarinique
GB0525254D0 (en)	2005-12-12	2006-01-18	Jagotec Ag	Powder compositions for inhalation
US7832397B2 (en)	2005-12-28	2010-11-16	Philip Morris Usa Inc.	Aerosol powder delivery device
GB0605723D0 (en) *	2006-03-23	2006-05-03	3M Innovative Properties Co	Powder filling processes
CA2739897C (fr)	2008-10-07	2017-10-03	Mpex Pharmaceuticals, Inc.	Formulations a base de fluoroquinolone sous forme d'aerosol pour une pharmacocinetique amelioree
US8629139B2 (en)	2008-10-07	2014-01-14	Mpex Pharmaceuticals, Inc.	Topical use of Levofloxacin for reducing lung inflammation
EP3578169B1 (fr)	2009-02-26	2024-06-26	Glaxo Group Limited	Préparations pharmaceutiques comprenant 4-{(1r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]éthoxy}hexyl)amino]-1-hydroxyéthyl}-2-(hydroxyméthyl)-phénol
EP2473170B1 (fr)	2009-09-04	2019-06-19	Horizon Orphan LLC	Utilisation de lévofloxacine en aérosol pour traiter la fibrose kystique
GB0918249D0 (en)	2009-10-19	2009-12-02	Respivert Ltd	Compounds
GB0921075D0 (en)	2009-12-01	2010-01-13	Glaxo Group Ltd	Novel combination of the therapeutic agents
BR112012026804B1 (pt) *	2010-04-21	2021-11-16	Chiesi Farmaceutici S.P.A.	Processo para preparar partículas carreadoras de uma formulação em pó seco para inalação e processo para preparar uma formulação em pó seco para inalação
TR201007250A2 (tr)	2010-09-01	2012-03-21	Bi̇lgi̇ç Mahmut	Selobioz içeren formülasyon.
UY33337A (es)	2010-10-18	2011-10-31	Respivert Ltd	DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
EP4059499A1 (fr)	2011-01-31	2022-09-21	Avalyn Pharma Inc.	Composés analogues de pyridone et de pirfénidone en aérosol, et leurs utilisations
ES2600705T3 (es)	2012-03-13	2017-02-10	Respivert Limited	Inhibidores de PI3 cinasa cristalinos
EP2641900A1 (fr)	2012-03-20	2013-09-25	Almirall, S.A.	Nouvelles formes polymorphes de héminapadisylate de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy) hexyl]amino}-1-(R)-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one en tant qu'agoniste du récepteur adrénergique ß2
MX354365B (es)	2012-07-19	2018-02-28	Adamis Pharmaceuticals Corp	Aparato alimentador de polvo.
GB201305825D0 (en)	2013-03-28	2013-05-15	Vectura Ltd	New use
JP6799201B2 (ja)	2013-07-31	2020-12-16	アヴァリンファーマインク．	エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
JP7066321B2 (ja)	2014-01-10	2022-05-13	アヴァリンファーマインク．	エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
DE102016218604A1 (de)	2016-09-27	2018-03-29	Constantin Adams	Partikuläres Stoffgemisch, vorzugsweise zur Verwendung bei der Prophylaxe und/oder Behandlung einer Atemwegsstörung
WO2022240897A1 (fr)	2021-05-10	2022-11-17	Sepelo Therapeutics, Llc	Composition pharmaceutique comprenant de la délafloxacine destinée à être administrée dans le poumon
WO2023028364A1 (fr)	2021-08-27	2023-03-02	Sepelo Therapeutics, Llc	Compositions ciblées et leurs utilisations
WO2023128916A1 (fr) *	2021-12-31	2023-07-06	Arven Ilac Sanayi Ve Ticaret Anonim Sirketi	Appareil à grille pour la préparation de compositions de poudre sèche pour inhalation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3957965A (en) *	1967-08-08	1976-05-18	Fisons Limited	Sodium chromoglycate inhalation medicament
DE3012136C2 (de) *	1980-03-28	1984-02-16	Bauer, Kurt Heinz, Prof. Dr., 7800 Freiburg	Verfahren zur Herstellung eines Granulats

1986
- 1986-03-04 IT IT19625/86A patent/IT1204826B/it active
1987
- 1987-02-27 AT AT87901468T patent/ATE94755T1/de not_active IP Right Cessation
- 1987-02-27 KR KR1019870701005A patent/KR940000099B1/ko not_active Expired - Lifetime
- 1987-02-27 ES ES198787102816T patent/ES2031839T3/es not_active Expired - Lifetime
- 1987-02-27 EP EP87901468A patent/EP0258356B1/fr not_active Expired - Lifetime
- 1987-02-27 HU HU871760A patent/HU202748B/hu not_active IP Right Cessation
- 1987-02-27 WO PCT/EP1987/000118 patent/WO1987005213A1/fr not_active Ceased
- 1987-02-27 DE DE198787901468T patent/DE258356T1/de active Pending
- 1987-02-27 AU AU71645/87A patent/AU597964B2/en not_active Ceased
- 1987-02-27 DE DE87901468T patent/DE3787502T2/de not_active Expired - Fee Related
- 1987-02-27 EP EP87102816A patent/EP0239798B1/fr not_active Expired - Lifetime
- 1987-02-27 JP JP62501911A patent/JPS63502895A/ja active Pending
- 1987-03-03 NZ NZ219484A patent/NZ219484A/xx unknown
- 1987-03-03 ZA ZA871523A patent/ZA871523B/xx unknown
- 1987-03-03 CA CA000531054A patent/CA1297012C/fr not_active Expired - Lifetime
- 1987-09-29 MY MYPI87002294A patent/MY102928A/en unknown
- 1987-10-26 FI FI874710A patent/FI90015C/fi not_active IP Right Cessation
- 1987-11-03 NO NO874590A patent/NO874590L/no unknown
1988
- 1988-05-20 GR GR88300017T patent/GR880300017T1/el unknown
1990
- 1990-09-27 GR GR90400695T patent/GR3000879T3/el unknown

Also Published As

Publication number	Publication date
GR880300017T1 (en)	1988-10-18
DE3787502D1 (de)	1993-10-28
MY102928A (en)	1993-03-31
GR3000879T3 (en)	1991-11-15
WO1987005213A1 (fr)	1987-09-11
AU7164587A (en)	1987-09-28
EP0258356B1 (fr)	1993-09-22
HU202748B (en)	1991-04-29
IT1204826B (it)	1989-03-10
FI874710A0 (fi)	1987-10-26
ES2031839T3 (es)	1993-01-01
NZ219484A (en)	1989-10-27
DE3787502T2 (de)	1994-01-20
FI90015C (fi)	1993-12-27
EP0239798B1 (fr)	1990-09-26
KR940000099B1 (ko)	1994-01-05
IT8619625A0 (it)	1986-03-04
KR880700666A (ko)	1988-04-11
JPS63502895A (ja)	1988-10-27
ZA871523B (en)	1987-08-24
FI874710L (fi)	1987-10-26
NO874590L (no)	1987-12-30
FI90015B (fi)	1993-09-15
EP0258356A1 (fr)	1988-03-09
EP0239798A1 (fr)	1987-10-07
AU597964B2 (en)	1990-06-14
HUT46533A (en)	1988-11-28
NO874590D0 (no)	1987-11-03
DE258356T1 (de)	1988-09-01
ATE94755T1 (de)	1993-10-15

Publication	Publication Date	Title
CA1297012C (fr)	1992-03-10	Compositiions pharmaceutiques pour inhalation
EP1007017B1 (fr)	2005-02-02	Nouvelle formulation pour inhalation ayant une masse volumique apparente de 0,28 a 0,38 g/ml, procede de preparation et utilisation de cette formulation
DE60104399T2 (de)	2005-09-08	Pulverformulierung zur inhalation
US6027714A (en)	2000-02-22	Formulation for inhalation
US8153104B2 (en)	2012-04-10	Pharmaceutical formulations for dry powder inhalers comprising a low-dosage strength active ingredient
EP1009394B1 (fr)	2004-01-14	Nouvelle formulation pour inhalation ayant une masse volumique de 0,28 a 0,38 g/ml et contenant du formoterol
US9987229B2 (en)	2018-06-05	Process for preparing a medicament
EP1014955B1 (fr)	2004-04-07	Nouvelle formulation pour inhalation ayant une densite en vrac de 0,28 a 0,38 g/ml et contenant du sulfate de terbutaline, procede de preparation et utilisation de cette formulation
US5980949A (en)	1999-11-09	Formulation for inhalation
WO2022045995A1 (fr)	2022-03-03	Procédé de préparation de compositions de poudre sèche pour inhalation
EP3672574A2 (fr)	2020-07-01	Compositions de poudre sèche à inhaler
WO2024010538A1 (fr)	2024-01-11	Procédé de préparation de compositions de poudre sèche pour inhalation à l'aide de différents mélangeurs
WO2022045993A1 (fr)	2022-03-03	Procédé de production de compositions de poudre sèche pour inhalation

Legal Events

Date	Code	Title	Description
1994-09-10	MKLA	Lapsed